α-tcs

TCS HDAC6 20b (HDAC6-IN-7) is a selective HDAC6 inhibitor that blocks the growth of breast cancer cells and may be used in the study of cancer and neurodegenerative diseases.

TCS PrP Inhibitor 13 (5-(4-Nitrophenyl)-2-Phenyl-4H-Pyrazol-3-One) is an antiprion agent inhibiting protease-resistant prion protein (PrP-res) accumulation.

TCS 2510 (CAY10598) is a selective PGE2 and EP4 receptor agonist that enhances the intracellular concentration of cAMP and the abundance of active β-caten.TCS 2510 inhibits TNF-alpha production and may be useful in the study of diseases associated with metabolic disorders.

TCS 21311 (NIBR3049) is an effective and highly selective inhibitor of JAK3 (IC50: 8 nM). TCS 21311 inhibits PKCα, PKCθ, and GSK3β (IC50s: 13, 68, and 3 nM, respectively). It displays >100-fold selectivity over JAK1, JAK2, and TYK2.

TCS 2314 (compound 3) is a potent and selective VLA-4 (α4β1 integrin; CD49d/CD29) antagonist with an IC50 of 4.4 nM. It exhibits high plasma clearance and low oral bioavailability in rats, making it suitable for asthma research.

GSK-3β inhibitor 9 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC 50 of 35 nM. GSK-3β inhibitor 9 exhibits good pharmacokinetic profiles including favorable BBB penetration. GSK-3β inhibitor 9 is able to be used for the research of Alzheimer's disease [1].

TCS PIM-1 1 (SC 204330)(sc-204330) is an effective and specific ATP-competitive Pim-1 kinase inhibitor (IC50: 50 nM), exhibiting good specificity over MEK1/MEK2 and Pim-2 (IC50s > 20,000 nM).

TCS 1105 is a GABAA benzodiazepine receptor (BZR) ligand. TCS 1105 blocks Sema3A induced axonal growth cones collapse. TCS 1105 reduces anxiety-like behavior and enhances offensive behavior and social dominance in mice.

TCS 2210 is an inducer of neuronal differentiation in mesenchymal stem cells and increases the neuronal markers β-III tubulin expression and neuron-specific enolase expression.

checkpoint kinase 1 (chk1) inhibitor

NR1A/NR2B NMDA receptor antagonist,orally active

TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).

Chembridge-5861528 (TCS 5861528) is a TRPA1 channel blocker that inhibits AITC- and 4-HNE-induced calcium influx with IC50 values of 14.3 μM and 18.7 μM, respectively.

TCS-OX2-29 is a potent and selective OX2 receptor antagonist (IC50: 40 nM). It displays >250-fold selectivity for OX2 over OX1.

TCS-OX2-29 is a selective orexin-2 receptor antagonist (IC50 = 40 nM), which plays an important role in pain modulation.

TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.

TCS-401 is an insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B).

TCS 401 is a selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) with a Ki value of 0.29 μM.

TCS 184 TFA is a peptide fragment.

DHBP (Benzoresorcinol) is an WalKR TCS activator. It works via targeting walk and selectively promoting the lysostaphin-induced lysis activity of the Newman wild-type strain.

TC-S 7005 is an effective inhibitor of Polo-like kinases (IC50s: 214 nM, 4 nM and 24 nM for Plk1, Plk2, and Plk3).

TC-S 7009 is a potent and selective HIF-2α inhibitor (Kd: 81 nM) with significantly higher affinity for HIF-2α than HIF-1α (Kd >> 5μM). TC-S 7009 disrupts HIF-2α heterodimerization, reduces HIF-2α target gene expression, and diminishes DNA binding activity.

GPR35 agonist 4 (compound 10) demonstrates high potency as a GPR35 agonist with a pEC50 of 5.86, effective on both human and rat GPR35; mutation of arginine at position 3.36 results in loss of its agonist function on GPR35 [1].

TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).